GB201202433D0 - Controlled drug release - Google Patents

Controlled drug release

Info

Publication number
GB201202433D0
GB201202433D0 GBGB1202433.7A GB201202433A GB201202433D0 GB 201202433 D0 GB201202433 D0 GB 201202433D0 GB 201202433 A GB201202433 A GB 201202433A GB 201202433 D0 GB201202433 D0 GB 201202433D0
Authority
GB
United Kingdom
Prior art keywords
core
hydrocortisone
delayed release
polymer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1202433.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine UK Ltd
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Priority to GBGB1202433.7A priority Critical patent/GB201202433D0/en
Publication of GB201202433D0 publication Critical patent/GB201202433D0/en
Priority to GB1302406.2A priority patent/GB2502402B/en
Priority to HUE13709499A priority patent/HUE048904T2/hu
Priority to SI201331723T priority patent/SI2814469T1/sl
Priority to SM20200286T priority patent/SMT202000286T1/it
Priority to RU2014130866A priority patent/RU2619869C2/ru
Priority to PL13709499T priority patent/PL2814469T3/pl
Priority to IN6808DEN2014 priority patent/IN2014DN06808A/en
Priority to JP2014556141A priority patent/JP6293678B2/ja
Priority to LTEP13709499.1T priority patent/LT2814469T/lt
Priority to MEP-2020-122A priority patent/ME03742B/me
Priority to BR112014020008-4A priority patent/BR112014020008B1/pt
Priority to US14/374,179 priority patent/US9750704B2/en
Priority to DK13709499.1T priority patent/DK2814469T3/da
Priority to HRP20200780TT priority patent/HRP20200780T1/hr
Priority to PT137094991T priority patent/PT2814469T/pt
Priority to EP13709499.1A priority patent/EP2814469B1/en
Priority to CN201910452557.1A priority patent/CN110141557A/zh
Priority to NZ627468A priority patent/NZ627468A/en
Priority to AU2013220139A priority patent/AU2013220139B2/en
Priority to MX2014009716A priority patent/MX361407B/es
Priority to KR1020147025024A priority patent/KR102023559B1/ko
Priority to CA2864031A priority patent/CA2864031C/en
Priority to PCT/GB2013/050311 priority patent/WO2013121184A1/en
Priority to CN201380008921.6A priority patent/CN104105481A/zh
Priority to ES13709499T priority patent/ES2792069T3/es
Priority to NZ715616A priority patent/NZ715616A/en
Priority to RS20200578A priority patent/RS60346B1/sr
Priority to HK15104320.6A priority patent/HK1203824A1/xx
Priority to IL234061A priority patent/IL234061B/en
Priority to ZA2015/08728A priority patent/ZA201508728B/en
Priority to IL245546A priority patent/IL245546A0/en
Priority to US15/641,650 priority patent/US10166194B2/en
Priority to CY20201100418T priority patent/CY1123202T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1202433.7A 2012-02-13 2012-02-13 Controlled drug release Ceased GB201202433D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
HK15104320.6A HK1203824A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
EP13709499.1A EP2814469B1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
CN201910452557.1A CN110141557A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂
SI201331723T SI2814469T1 (sl) 2012-02-13 2013-02-12 Formulacije hidrokortizona s prirejenim sproščanjem
SM20200286T SMT202000286T1 (it) 2012-02-13 2013-02-12 Formulazione a rilascio controllato di idrocortisone
RU2014130866A RU2619869C2 (ru) 2012-02-13 2013-02-12 Композиция гидрокортизона с контролируемым высвобождением
PL13709499T PL2814469T3 (pl) 2012-02-13 2013-02-12 Postać użytkowa hydrokortyzonu o kontrolowanym uwalnianiu
IN6808DEN2014 IN2014DN06808A (enEXAMPLES) 2012-02-13 2013-02-12
JP2014556141A JP6293678B2 (ja) 2012-02-13 2013-02-12 ハイドロコーチゾンの制御放出製剤
LTEP13709499.1T LT2814469T (lt) 2012-02-13 2013-02-12 Hidrokortizono kontroliuojamo atpalaidavimo kompozicija
MEP-2020-122A ME03742B (me) 2012-02-13 2013-02-12 Formulacija oslobađanja kontrolisanom hidrokortizonom
AU2013220139A AU2013220139B2 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
US14/374,179 US9750704B2 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
DK13709499.1T DK2814469T3 (da) 2012-02-13 2013-02-12 Hydrocortisonformulering med controlled release
HRP20200780TT HRP20200780T1 (hr) 2012-02-13 2013-02-12 Formulacija za kontrolirano otpuštanje hidrokortizona
PT137094991T PT2814469T (pt) 2012-02-13 2013-02-12 Formulação de hidrocortisona de libertação controlada
GB1302406.2A GB2502402B (en) 2012-02-13 2013-02-12 Controlled drug release
NZ627468A NZ627468A (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
HUE13709499A HUE048904T2 (hu) 2012-02-13 2013-02-12 Szabályozott hatóanyag-leadású hidrokortizon készítmény
BR112014020008-4A BR112014020008B1 (pt) 2012-02-13 2013-02-12 Composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação
MX2014009716A MX361407B (es) 2012-02-13 2013-02-12 Formulaciones de liberacion controlada de hidrocortisona.
KR1020147025024A KR102023559B1 (ko) 2012-02-13 2013-02-12 제어형 하이드로코티손 방출 제형
CA2864031A CA2864031C (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation
CN201380008921.6A CN104105481A (zh) 2012-02-13 2013-02-12 氢化可的松控制释放制剂
ES13709499T ES2792069T3 (es) 2012-02-13 2013-02-12 Formulación de liberación controlada de hidrocortisona
NZ715616A NZ715616A (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formation
RS20200578A RS60346B1 (sr) 2012-02-13 2013-02-12 Formulacija oslobađanja kontrolisanim hidrokortizonom
IL234061A IL234061B (en) 2012-02-13 2014-08-11 Controlled release hydrocortisone formulation
ZA2015/08728A ZA201508728B (en) 2012-02-13 2015-11-30 Hydrocortisone controlled release formulation
IL245546A IL245546A0 (en) 2012-02-13 2016-05-09 Controlled release hydrocortisone formulation
US15/641,650 US10166194B2 (en) 2012-02-13 2017-07-05 Hydrocortisone controlled release formulation
CY20201100418T CY1123202T1 (el) 2012-02-13 2020-05-06 Σκευασμα υδροκορτιζονης ελεγχομενης απελευθερωσης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release

Publications (1)

Publication Number Publication Date
GB201202433D0 true GB201202433D0 (en) 2012-03-28

Family

ID=45930017

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1202433.7A Ceased GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
GB1302406.2A Active GB2502402B (en) 2012-02-13 2013-02-12 Controlled drug release

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1302406.2A Active GB2502402B (en) 2012-02-13 2013-02-12 Controlled drug release

Country Status (29)

Country Link
US (2) US9750704B2 (enEXAMPLES)
EP (1) EP2814469B1 (enEXAMPLES)
JP (1) JP6293678B2 (enEXAMPLES)
KR (1) KR102023559B1 (enEXAMPLES)
CN (2) CN104105481A (enEXAMPLES)
AU (1) AU2013220139B2 (enEXAMPLES)
BR (1) BR112014020008B1 (enEXAMPLES)
CA (1) CA2864031C (enEXAMPLES)
CY (1) CY1123202T1 (enEXAMPLES)
DK (1) DK2814469T3 (enEXAMPLES)
ES (1) ES2792069T3 (enEXAMPLES)
GB (2) GB201202433D0 (enEXAMPLES)
HK (1) HK1203824A1 (enEXAMPLES)
HR (1) HRP20200780T1 (enEXAMPLES)
HU (1) HUE048904T2 (enEXAMPLES)
IL (2) IL234061B (enEXAMPLES)
IN (1) IN2014DN06808A (enEXAMPLES)
LT (1) LT2814469T (enEXAMPLES)
ME (1) ME03742B (enEXAMPLES)
MX (1) MX361407B (enEXAMPLES)
NZ (2) NZ715616A (enEXAMPLES)
PL (1) PL2814469T3 (enEXAMPLES)
PT (1) PT2814469T (enEXAMPLES)
RS (1) RS60346B1 (enEXAMPLES)
RU (1) RU2619869C2 (enEXAMPLES)
SI (1) SI2814469T1 (enEXAMPLES)
SM (1) SMT202000286T1 (enEXAMPLES)
WO (1) WO2013121184A1 (enEXAMPLES)
ZA (1) ZA201508728B (enEXAMPLES)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
AU2022209123A1 (en) 2021-01-15 2023-07-06 Galventa Ag Pulsatile release caffeine formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO2002017887A1 (de) * 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
KR20040025741A (ko) * 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
NZ532564A (en) 2001-11-23 2006-06-30 Procter & Gamble Solid unit dosage forms for oral administration which minimise the impact of coating fractures especially for larger or heavier dosage forms
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
JP2009545546A (ja) * 2006-08-03 2009-12-24 ニテック ファーマ アクチエンゲゼルシャフト リウマチ性疾患の遅延放出型グルココルチコイド治療
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
SG174583A1 (en) * 2009-04-07 2011-10-28 Duocort Pharma Ab Improved glucocorticoid therapy
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
IT1405012B1 (it) * 2010-08-06 2013-12-16 Sofar Spa Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Also Published As

Publication number Publication date
AU2013220139B2 (en) 2017-08-31
IL234061B (en) 2018-03-29
KR102023559B1 (ko) 2019-09-23
GB2502402A (en) 2013-11-27
US20140370113A1 (en) 2014-12-18
NZ627468A (en) 2016-02-26
CA2864031C (en) 2019-11-12
US9750704B2 (en) 2017-09-05
SI2814469T1 (sl) 2020-07-31
EP2814469B1 (en) 2020-04-08
EP2814469A1 (en) 2014-12-24
BR112014020008B1 (pt) 2022-05-24
US20170296475A1 (en) 2017-10-19
CN104105481A (zh) 2014-10-15
CY1123202T1 (el) 2021-10-29
KR20140121478A (ko) 2014-10-15
IL245546A0 (en) 2016-06-30
CN110141557A (zh) 2019-08-20
PT2814469T (pt) 2020-05-22
MX361407B (es) 2018-12-04
HK1203824A1 (en) 2015-11-06
PL2814469T3 (pl) 2020-07-13
AU2013220139A1 (en) 2014-08-07
BR112014020008A8 (pt) 2018-01-23
IN2014DN06808A (enEXAMPLES) 2015-05-22
LT2814469T (lt) 2020-05-25
IL234061A0 (en) 2014-09-30
HUE048904T2 (hu) 2020-08-28
RS60346B1 (sr) 2020-07-31
HRP20200780T1 (hr) 2020-10-02
ME03742B (me) 2021-04-20
NZ715616A (en) 2017-03-31
JP2015506972A (ja) 2015-03-05
SMT202000286T1 (it) 2020-07-08
CA2864031A1 (en) 2013-08-22
ES2792069T3 (es) 2020-11-06
RU2014130866A (ru) 2016-04-10
RU2619869C2 (ru) 2017-05-18
JP6293678B2 (ja) 2018-03-14
US10166194B2 (en) 2019-01-01
ZA201508728B (en) 2017-09-27
MX2014009716A (es) 2015-01-14
WO2013121184A1 (en) 2013-08-22
GB2502402B (en) 2014-11-12
DK2814469T3 (da) 2020-05-04
GB201302406D0 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
GB201302406D0 (en) Controlled drug release
ZA202400983B (en) Polymer protein microparticles
ZA202304376B (en) Compositions and methods of manufacturing protein microparticles
WO2011077451A3 (en) Controlled release pharmaceutical composition
WO2011049309A3 (ko) 속효성과 지속성을 동시에 갖는 약제학적 조성물
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
NZ604646A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
HK1244429A1 (zh) 特别用於治疗注意力缺陷障碍的方法和组合物
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
EP2338917A4 (en) SULFATED DERIVATIVE FROM A GASTRODIA ELATA POLYSACCHARIDE AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2583969A4 (en) NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
HK1216839A1 (zh) 调整释放制剂
WO2012092486A3 (en) Modified release benzimidazole formulations
NZ631426A (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
WO2013017910A8 (en) Extended release pharmaceutical compositions containing paliperidone
PL2201940T3 (pl) Kompozycja biokompatybilnych mikrocząstek kwasu alginowego do kontrolowanego uwalniania substancji czynnej po podaniu dożylnym
CA2733299A1 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
MX2012013362A (es) Una composicion farmaceutica de liberacion controlada de losartan.
HK1195491A1 (zh) 受控药物释放
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)